Publicaciones en colaboración con investigadores/as de Universitat Autònoma de Barcelona (24)

2024

  1. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

2023

  1. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

    Cancers, Vol. 14, Núm. 12

2021

  1. A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors

    Radiology, Vol. 299, Núm. 1, pp. 109-119

  2. Atezolizumab in locally advanced or metastatic urothelial cancer: a pooled analysis from the Spanish patients of the IMvigor 210 cohort 2 and 211 studies

    Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 882-891

  3. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

    European Journal of Cancer, Vol. 155, pp. 168-178

2020

  1. Capturing hyperprogressive disease with immune-checkpoint inhibitors using RECIST 1.1 criteria

    Clinical Cancer Research, Vol. 26, Núm. 8, pp. 1846-1855

  2. Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma

    Clinical Genitourinary Cancer, Vol. 18, Núm. 6, pp. 452-460

  3. Identification of expression profiles defining distinct prognostic subsets of radioactive-iodine refractory differentiated thyroid cancer from the DECISION trial

    Molecular Cancer Therapeutics, Vol. 19, Núm. 1, pp. 312-317

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017) (Clinical and Translational Oncology, (2018), 20, 1, (47-56), 10.1007/s12094-017-1765-4)

    Clinical and Translational Oncology

  3. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer

    International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 1050-1056

  4. Triple-drug chemotherapy regimens in combination with an anti-EGFR agent in metastatic colorectal cancer - prospects from phase II clinical trials

    Expert Opinion on Investigational Drugs, Vol. 28, Núm. 5, pp. 463-471

2018

  1. Early evolutionary divergence between papillary and anaplastic thyroid cancers

    Annals of Oncology, Vol. 29, Núm. 6, pp. 1454-1460

  2. Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer

    Expert Opinion on Pharmacotherapy, Vol. 19, Núm. 6, pp. 623-629

  3. SEOM clinical guideline for treatment of kidney cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 47-56

  4. The safety of ramucirumab for the treatment of colorectal cancer

    Expert Opinion on Drug Safety, Vol. 17, Núm. 9, pp. 945-951

2017

  1. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

    OncoTargets and Therapy, Vol. 10, pp. 4635-4643

  2. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

2016

  1. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

    Oncotarget, Vol. 7, Núm. 35, pp. 56295-56308